Biological medicines have made substantial contributions to the treatment of many chronic and serious diseases and are expected to provide significant therapeutic benefits to many patients who would otherwise have had limited treatment options.
Increasingly aging populations and this growing burden of chronic diseases have put tremendous pressure on healthcare systems all over the world, increasing demand for cost effective medicines.
This has opened up huge opportunities for follow-on biologics, or biosimilars, to enter the market and serve the needs of patients all over the world in a cost effective manner.
